|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Sac1 Domain of SYNJ 1 Identified Mutated in a Family with Early‐Onset Progressive P arkinsonism with Generalized Seizures显示文摘 | Catharine E. Krebs Siamak Karkheiran James C. Powell Mian Cao Vladimir Makarov Hossein Darvish Gilbert Di Paolo Ruth H. Walker Gholam Ali Shahidi Joseph D. Buxbaum Pietro De Camilli Zhenyu Yue Coro Paisán‐Ruiz | 2013 | Human Mutation2013，，9： | 1 |
| 2 | Baselines for land-use change in the tropics: application to avoided deforestation projects显示文摘 | Sandra Brown Myrna Hall Ken Andrasko Fernando Ruiz Walter Marzoli Gabriela Guerrero Omar Masera Aaron Dushku Ben DeJong Joseph Cornell | 2007 | Mitigation and Adaptation Strategies for Global Change2007，，6： | 1 |
| 3 | Does deep sedation with propofol affect adenoma detection rates in average risk screening colonoscopy exams?显示文摘AIM To determine the effect of sedation with propofol on adenoma detection rate(ADR) and cecal intubation rates(CIR) in average risk screening colonoscopies compared to moderate sedation.METHODS We conducted a retrospective chart review of 2604 firsttime average risk screening colonoscopies performed at MD Anderson Cancer Center from 2010-2013. ADR and CIR were calculated in each sedation group. Multivariable regression analysis was performed to adjust for potential confounders of age and body mass index(BMI). RESULTS One-third of the exams were done with propofol(n = 874). Overall ADR in the propofol group was significantly higher than moderate sedation(46.3% vs 41.2%, P = 0.01). After adjustment for age and BMI differences, ADR was similar between the groups. CIR was 99% for all exams. The mean cecal insertion time was shorter among propofol patients(6.9 min vs 8.2 min; P < 0.0001).CONCLUSION Deep sedation with propofol for screening colonoscopy did not significantly improve ADR or CIR in our population of average risk patients. While propofol may allow for safer sedation in certain patients(e.g., with sleep apnea), the overall effect on colonoscopy quality metrics is not significant. Given its increased cost, propofol should be used judiciously and without the implicit expectation of a higher quality screening exam. | Selvi Thirumurthi Gottumukkala S Raju Mala Pande Joseph Ruiz Richard Carlson Katherine B Hagan Jeffrey H Lee William A Ross | 2017 | World Journal of Gastrointestinal Endoscopy2017，9，4： | 1 |
| 4 | CUL - 4A is chtical for early embryonic development 显示文摘 | Binghui Li Joseph C Ruiz Kristin T Chun | 2002 | Molecular and cellular biology2002，22，14： | 1 |
| 5 | Multisociety (AATS, ACCF, SCAI, and STS) expert consensus statement: Operator and institutional requirements for transcatheter valve repair and replacement, part 1: Transcatheter aortic valve replacement显示文摘 | Carl L. Tommaso R. Morton Bolman Ted Feldman Joseph Bavaria Michael A. Acker Gabriel Aldea Duke E. Cameron Larry S. Dean Dave Fullerton Ziyad M. Hijazi Eric Horlick D. Craig Miller Marc R. Moon Richard Ringel Carlos E. Ruiz Alfredo Trento Bonnie H. Weiner | 2012 | The Journal of Thoracic and Cardiovascular Surgery2012，，： | 1 |
| 6 | Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations显示文摘The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials. | Federico Rodriguez-Porcel Kathryn A.Wyman-Chick Carla Abdelnour Ruiz Jon B.Toledo Daniel Ferreira Prabitha Urwyler Rimona S.Weil Joseph Kane Andrea Pilotto Arvid Rongve Bradley Boeve John-Paul Taylor Ian McKeith Dag Aarsland Simon J.G.Lewis the Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area-Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment(ISTAART) | 2022 | Translational Neurodegeneration2022，11，1： | 0 |
| 7 | Correction:Clinical outcome measures in dementia with Lewy bodies trials:critique and recommendations显示文摘Correction to:Translational Neurodegeneration(2022)11:24 http://gffzzd3cc09b8251d45dfspf9n66wkqv6n6fu6.ffgz.tsg.suse.edu.cn/10.1186/s40035-022-00299-w Following publication of the original article[1],the authors identified some errors in the Additional files 1-5.The original article[1]has been corrected. | Federico Rodriguez-Porcel Kathryn A.Wyman-Chick Carla Abdelnour Ruiz Jon B.Toledo Daniel Ferreira Prabitha Urwyler Rimona S.Weil Joseph Kane Andrea Pilotto Arvid Rongve Bradley Boeve John-Paul Taylor Ian McKeith Dag Aarsland Simon J.G.Lewis the Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area-Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment(ISTAART) | 2022 | Translational Neurodegeneration2022，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员